Although we don't believe in timing the market or panicking over market movements, we do like to keep an eye on big changes -- just in case they're material to our investing thesis.
What: Shares of Amarin Corporation are down over 20% today after the Office of New Drugs within the Food and Drug Administration denied Amarin's latest appeal to reinstate the Special Protocol Assessment, or SPA, agreement for the ANCHOR clinical trial, designed to expand the label of the company's prescription fish-oil pill called Vascepa. As a refresher, the FDA repealed the ANCHOR SPA last October after questioning the clinical trial's design and ability of fish oil pills in general to improve cardiovascular outcomes.
Vascepa is currently approved as a treatment for patients with severely high (≥ 500 mg/dL) triglyceride levels through the so-called MARINE indication. The ANCHOR trial data would expand the label to include adults with moderately high triglycerides (TG ≥200 mg/dL &
So What: Amarin is desperate to increase sales of its prescription fish oil pill and the coveted label expansion looked like the ticket to achieve this goal. Now that a near-term label expansion is potentially off the table, the company may have to seriously consider curtailing its other clinical activities as a cost-savings measure.
Now What: This is Amarin's third, and potentially last available, attempt at getting the ANCHOR SPA reinstated. So at this point, the company could finally concede defeat and reassess its options moving forward. That said, Amarin did state in its press release that they are "evaluating potential next steps" in regards to fighting the FDA's decision on the matter. That could mean yet another appeal to an even higher official within the FDA.
With generic versions of GlaxoSmithKline 's competing fish oil pill, Lovaza, now on the market and a host of stellar cholesterol lowering drugs under regulatory review, Amarin looks like a company in deep trouble following its inability to get ANCHOR's SPA reinstated. Consequently, you may want to sit safely on the sidelines with this speculative biotech.
This coming blockbuster will make every biotech jealous
The best biotech investors consistently reap gigantic profits by recognizing true potential earlier and more accurately than anyone else. Let me cut right to the chase. There is a product in development that will revolutionize not just how we treat a common chronic illness, but potentially the entire health industry. Analysts are already licking their chops at the sales potential. In order to outsmart Wall Street and realize multi-bagger returns you will need The Motley Fool's new free report on the dream-team responsible for this game-changing blockbuster. CLICK HERE NOW .
The article Why Amarin Corporation plc Stock Cratered originally appeared on Fool.com.
George Budwell has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days . We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy .
Copyright © 1995 - 2014 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy .